Credit: Dana-Farber Cancer Institute
Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with multiple myeloma and breast cancer. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).